Urokinase (u-PA) is Produced by Collecting Duct Principal Cells and is Post-transcriptionally Regulated by SV40 Large-T, Arginine Vasopressin, and Epidermal Growth Factor
Overview
Physiology
Affiliations
We have analyzed the expression and regulation of plasminogen activators (PA) in principal cells of the renal collecting duct. We used a rabbit principal cell line (RC.SVtsA58) infected with the temperature-sensitive SV40 strain tsA58. Transformed cells cultured at permissive temperature (33 degrees C) produced only tissue-type plasminogen activator (t-PA). Shifting the cells to nonpermissive temperature (39.5 degrees C) induced their differentiation and a marked increase in total fibrinolytic activity due to the induction of urokinase-type plasminogen activator (u-PA) synthesis and secretion. The effect on u-PA was post-transcriptional and it could be attributed to large-T inactivation at 39.5 degrees C since it was abolished by re-infecting the cells with wild-type SV40. Run-on assay and real-time RT-PCR of u-PA transcripts indicated that large-T altered post-transcriptional regulation. u-PA was also produced by primary cultures of collecting duct cells and was present in the rabbit urine. In the kidney, u-PA and its receptor (u-PAR) were almost exclusively expressed at the apex of collecting duct cells. We then analyzed the regulation of u-PA by arginine vasopressin (AVP) and epidermal growth factor (EGF), two key regulators of principal cell functions. We found that AVP and EGF, which have opposite hydro-osmotic effects in the collecting duct, also exhibited contrasted effects on u-PA synthesis in differentiated RC.SVtsA58 cells. EGF increased but AVP suppressed u-PA activity and protein, and these regulations occurred at post-transcriptional level. These results point to a physiological role of u-PA in principal cells of the renal collecting duct.
Trial of Amiloride in Type 2 Diabetes with Proteinuria.
Unruh M, Pankratz V, Demko J, Ray E, Hughey R, Kleyman T Kidney Int Rep. 2017; 2(5):893-904.
PMID: 28890943 PMC: 5584552. DOI: 10.1016/j.ekir.2017.05.008.
Physiology and pathophysiology of the plasminogen system in the kidney.
Svenningsen P, Hinrichs G, Zachar R, Ydegaard R, Jensen B Pflugers Arch. 2017; 469(11):1415-1423.
PMID: 28656379 DOI: 10.1007/s00424-017-2014-y.
Sodium retention and volume expansion in nephrotic syndrome: implications for hypertension.
Ray E, Rondon-Berrios H, Boyd C, Kleyman T Adv Chronic Kidney Dis. 2015; 22(3):179-84.
PMID: 25908466 PMC: 4409655. DOI: 10.1053/j.ackd.2014.11.006.
Haerteis S, Krappitz M, Diakov A, Krappitz A, Rauh R, Korbmacher C J Gen Physiol. 2012; 140(4):375-89.
PMID: 22966015 PMC: 3457690. DOI: 10.1085/jgp.201110763.
ENaCs and ASICs as therapeutic targets.
Qadri Y, Rooj A, Fuller C Am J Physiol Cell Physiol. 2012; 302(7):C943-65.
PMID: 22277752 PMC: 3330738. DOI: 10.1152/ajpcell.00019.2012.